University of Notre Dame du Lac’s BioCryst Pharmaceuticals BCRX Stock Holding History

University of Notre Dame du Lac’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-489,196	Closed	-$1.85M	–	58
2019 Q2	$1.85M	Buy	+489,196	New	+$2.94M	0.42%	56
2017 Q3	–	Sell	-422,767	Closed	-$2.35M	–	74
2017 Q2	$2.35M	Buy	422,767 +100,603	+31%	+$613K	0.69%	67
2017 Q1	$2.71M	Buy	+322,164	New	+$2.24M	0.68%	53

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

University of Notre Dame du Lac's BCRX Position: Q3 2019 in Review

University of Notre Dame du Lac sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2019, closing a stake of 489,196 shares — an estimated $1.85M sold.

University of Notre Dame du Lac first reported a position in BCRX in Q1 2017 and held it in 3 quarters. The position peaked at $2.71M in Q1 2017. 115 funds tracked by Wall St. Rank hold BCRX as of Q3 2019.

University of Notre Dame du Lac reported no remaining BioCryst Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
University of Notre Dame du Lac sold 489,196 BioCryst Pharmaceuticals shares in Q3 2019, an estimated $1.85M.
University of Notre Dame du Lac first reported a position in BioCryst Pharmaceuticals in Q1 2017 and held it in 3 quarters.
University of Notre Dame du Lac's BioCryst Pharmaceuticals position peaked at $2.71M in Q1 2017.
115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2019.

Based on University of Notre Dame du Lac's 13F filing for Q3 2019, filed 13 Nov 2019.